Certifications
Gastroenterology
American Board of Internal Medicine
Clinical Focus
- Alcohol Hepatitis
- Cirrhosis
- Colon Polypectomy
- Colonoscopy
- Encephalitis
- End-Stage Liver Disease
- Endoscopic Band Ligation
- Esophageal Varices
- Flexible Sigmoidoscopy
- Gastrostomy: Permanent And Temporary
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Hepatitis E
- Hepatocellular Carcinoma
- Hepatorenal Syndrome
- Liver Biopsy
- Liver Cancer
- Liver Failure/Liver Transplantation
- Liver Fibrosis
- Liver Transplant
- Paracentesis
- Pretransplant Evaluation
- Upper GI Endoscopy
- Upper GI Endoscopy, Diagnostic
- Variceal Band Ligation
Education
MD, New York Medical College
Residency, Internal Medicine
Winthrop University HospitalFellowship, Gastroenterology
Winthrop University HospitalFellowship, Transplant Hepatology
Mount Sinai School of Medicine
Biography
Dr. Gene Y Im is an Assistant Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He earned his B.A. from the University of California, Berkeley, graduating with honors. He completed his Internal Medicine residency at Winthrop-University Hospital, the primary teaching affiliate for the SUNY Stony Brook School of Medicine. He continued at Winthrop to complete his fellowship training in Gastroenterology, followed by an advanced fellowship in Transplant Hepatology at the Mount Sinai Medical Center. He has given several oral presentations and presented posters of his research at international meetings such as AASLD, DDW, ACG and NYSGE.
Dr. Im’s areas of clinical interest include cirrhosis, acute/chronic liver diseases, portal hypertension, liver biopsy, quality improvement, inpatient care of liver patients and liver transplantation. His research program focuses on clinical aspects of liver diseases such as alcoholic liver disease, viral hepatitis, portal hypertension, liver biopsy and interpretation and outcomes-based research.
Dr. Im is an UNOS-certified Liver Transplant physician and is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology. He is also a member of the American Association for the Study of Liver Diseases.
Visit RMTI website: www.mountsinaiRMTI.org
Research
Emerging Therapies for Severe Alcoholic Hepatitis
Early liver transplantation for severe alcoholic hepatitis has recently been demonstrated to be a feasible and effective therapy for highly selected patients who fail medical therapy and violate the so-called “6 month rule,” using a rigorous evaluation program. Here at Mount Sinai, we are considering early liver transplantation as a rescue therapy for selected patients with severe alcoholic hepatitis. This is likely one of the first organized experiences with this treatment approach outside of France. Particular areas of interest include patient selection, evaluation, complications, outcomes, burden on organ supply, recidivism and psychosocial evaluation and follow up after transplantation. Translational collaborations are being planned with the Alcoholic Liver Disease Research Center at Mount Sinai to further elucidate the pathogenesis of alcoholic hepatitis. Future clinical trials to evaluate therapies with less side-effects, more targeted therapies or those aimed hepatic regeneration are needed.
Fluid and Tissue Characteristics in Liver Diseases
Outcomes of Inpatient Hospital Transfers to a Liver Transplant Center
The purpose of this study is to examine the characteristics and outcomes of patients referred for inpatient hospital transfer to Mount Sinai Medical Center. These patients anecdotally have poor clinical outcomes, but a systematic evaluation of this special population has not been performed. Multivariate analysis demonstrated that patients with acute on chronic liver failure or sepsis were more likely to have inpatient mortality, P=.03, OR 3.03. This single center experience demonstrates that while inpatient transfers to a liver transplant center lead to successful discharging of <75%, very few evaluations and even fewer liver transplant were performed after transfer, with at least 6 months of follow up. Most of the transferred patients have known liver disease and their rate of inpatient mortality suggests the need for earlier referral to a liver transplant center. Future efforts will focus on a cost-effectiveness analysis of inpatient hospital transfers to the liver service.Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Im is not currently required to report Industry relationships.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 4th Floor
1425 Madison Avenue
New York, NY 10029
Fax: 212-731-7245
